Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
NEW HOPE, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an industry-sponsored satellite symposium at the Heart Rhythm Society (“HRS”) 2025 Annual Meeting, taking place April 24–27, 2025, in San Diego, California featuring recent advancements in the Company’s atrioventricular interval modulation (“AVIM”) therapy program. The April 25th, 6:45 am PT symposium titled “The Future of Cardiac Pacing: Unlocking the Potential of Atrioventricular Interval Modulation (AVIM) Therapy” will convene leading electrophysiologists, hypertension and heart failure specialists to discuss the unmet need in hypertension, AVIM therapy mechanism of action, and growing body of clinical evidence supporting this novel therapy for the treatment of patients with uncontrolled hypertension who have increased cardiovascular risk with or without an indication for a pacemaker.
A wave of groundbreaking announcements this week has put the spotlight on several micro- and small-cap innovators shaping the future of healthcare, biotech, and clean energy—earning high-level regulatory, federal, and commercial support.
Medtronic delivers consistent dividend growth and healthcare innovation, positioning it as a stable investment choice in today's dynamic market environment.
NEW HOPE, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Breakthrough Device Designation (“BDD”) for atrioventricular interval modulation (“AVIM”) therapy.
Healthcare sector sees volatility due to UnitedHealth's earnings disappointment, but ETFs like XLV, IHE, and XPH still show resilience and pockets of strength.
The device, known as the Layer 7 Cortical Interface, is a thin, flexible microelectrode array designed to record and stimulate neural activity without penetrating brain tissue.
U.S. major indices traded lower at midday Wednesday, pressured by sharp declines in tech and semiconductor stocks after Washington tightened chip export restrictions to China.
PALM BEACH, Fla., April 16, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Artificial intelligence (AI) is being utilized for disease detection in the global markets. In today’s AI-driven world, the use of deep learning algorithms and AI tools in diagnostics can improve the accuracy, speed and efficiency for diagnosing patients with minimal errors. The introduction of AI tools in diagnostics has revolutionized the healthcare industry with supporting the doctors in advanced disease diagnosis and providing personalized treatments to patients with better judgements and quick results. According to Precedence Research, the global artificial intelligence in diagnostics market size was exhibited at USD 1.61 billion in 2024 and is projected to hit around USD 8.54 billion by 2033, growing at a CAGR of 20.37% during the forecast period 2024 to 2033. The report said: “The advances in digital biomarkers technology which uses real-time monitoring systems for early disease diagnosis and prediction has also enhanced the AI in diagnostics market growth. The application of AI tools in diagnostics has led to analyzing medical images for assessing disease progression, predicting patient outcomes, processing and storing of patient data which includes electronic health records (EHRs), identifying patterns and anomalies in patient data and symptom checkers for providing potential diagnosis.” Active healthcare/tech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Illumina Inc. (NASDAQ: ILMN), Tempus AI, Inc. (NASDAQ: TEM), Medtronic plc (NYSE: MDT), Spectral AI, Inc. (NASDAQ: MDAI).
(NewsUSA) - As the cold of winter fades, spring brings a fresh sense of renewal—and for many, it’s the first time in months they’ll be showing off their legs again. But for some, the thought of revealing their legs can come with hesitation. This may be especially true for those with varicose veins.
SAN FRANCISCO, Calif., March 31, 2025 (SEND2PRESS NEWSWIRE) -- Neurotech Reports, the publisher of the newsletter Neurotech Business Report, announced the availability of a new market research report that forecasts the growth of the worldwide market for implanted pain neuromodulation systems. According to the newly published report, "The Market for Implanted Pain Neuromodulation Systems: 2025-2030," the worldwide market will be $3.37 billion in 2025, growing to $6.49 billion by 2030, which represents a 12% compound annual growth rate. - News from Neurotech Reports, issued by Send2Press Newswire
(NewsUSA) - As the cold of winter fades, spring brings a fresh sense of renewal—and for many, it’s the first time in months they’ll be showing off their legs again. But for some, the thought of revealing their legs can come with hesitation. This may be especially true for those with varicose veins.
China is stepping up efforts to reassure U.S. corporate giants like Apple, Pfizer, and Mastercard of its economic potential, with Vice Premier He Lifeng promising a better business environment amid rising U.S. tariff pressures and slowing foreign investment.
(NewsUSA) - As the cold of winter fades, spring brings a fresh sense of renewal—and for many, it’s the first time in months they’ll be showing off their legs again. But for some, the thought of revealing their legs can come with hesitation. This may be especially true for those with varicose veins.
